A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy

Iannazzo, Sergio; Distante, Chiara; Lopatriello, Stefania

doi:10.5301/grhta.5000274

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As far as healthcare costs are concerned, a recent Italian study showed mCRC patients treated with bevacizumab or cetuximab combined with standard CT (i.e., capecitabine, FOLFOXIRI, XELOX or FOLFOX4) had direct costs ranging from 16 thousand euros to 43 thousand euros, assuming a duration of 6.1 months for each treatment regimen [14]. These data are not so far from our cost estimate which is around 60 thousand euros in a 60-month timespan.…”

Section: Discussionmentioning

confidence: 56%

Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project

Franchi

Garau²,

Kirchmayer

et al. 2020

Cancers

View full text Add to dashboard Cite

Evidence available on the effectiveness and costs of biological therapies for the initial treatment of metastatic colorectal cancer (mCRC) is scarce and contrasting. We conducted a population-based cohort investigation for assessing overall survival and costs associated with their use in a real-world setting. Healthcare utilization databases were used to select patients newly diagnosed with mCRC between 2010 and 2016. Those initially treated with biological therapy (bevacizumab or cetuximab) added to chemotherapy were propensity-score-matched to those treated with standard chemotherapy alone, and were followed up to June 30th, 2018. Kaplan–Meier survival estimates, restricted mean survival time (RMST) and cumulative costs were compared between the two treatment arms. The study cohort included 1896 mCRC patients treated with biological therapy matched to 5678 patients treated with chemotherapy alone. Median overall survival was 21.8 and 20.2 months, respectively. After 84 months of follow-up, RMSTs were 30.9 and 31.9 months (p = 0.193), indicating no differences between the average survival time between treatment arms. Patients treated with biological therapy were associated with higher costs. Cumulative per capita costs were €59,663 and €44,399, respectively. In our study, first-line biological therapy did not improve long-term overall survival and was associated with higher costs as compared to standard chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 56%

Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project

Franchi

Garau²,

Kirchmayer

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer is caused by the abnormal proliferation of intestinal mucosal cells and consequently, the interaction between environmental and genetic factors. 1 Exposure to these factors as well as the formation and persistence of defective DNA causes mutations and genetic changes. As a result, this process leads to cell transformation and growth, and eventually colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran

et al. 2023

View full text Add to dashboard Cite

Background Colorectal cancer is one of the most common cancers in the world, with about one million cases diagnosed annually. Various treatment methods can be used to treat colorectal cancer, including chemotherapy with different drug regimens. Considering the need to opt for more effective and less expensive drugs in the treatment of this disease, the present study aimed to compare the cost-effectiveness of FOLFOX6+Bevacizumab with FOLFOX6+Cetuximab in patients with stage IV colorectal cancer referred to medical centers in Shiraz, Iran, in 2021. Materials and Methods Using a decision tree, the cost-effectiveness and cost-utility of the 2 drug regimens were compared in all studied patients through the census method. Having a societal perspective, this study considered direct medical costs, direct non-medical costs, and indirect costs. The effectiveness indicators included the rate of major response to the drug combination used and the Quality-adjusted Life Year (QALY). The data were analyzed using Treeage 2011 and Excel 2016 software. In order to ensure the robustness of the results, one-way and probabilistic sensitivity analyses were performed as well. Results The results showed that the expected costs, the effectiveness (major response rate), and the QALYs of the FOLFOX6+Bevacizumab drug regimen were $16746.13(USD), .49, and .19, respectively, and those of the FOLFOX6+Cetuximab regimen were, respectively, $15191.05 (USD), .68, and .22. Therefore, FOLFOX6+Cetuximab compared to FOLFOX6+Bevacizumab was less costly and more effective and had a greater QALY, thus being considered as the dominant option. Also, the results of the sensitivity analyses showed that there was a bit of uncertainty. Conclusion Considering that the FOLFOX6+Cetuximab regimen was more cost-effective, it is suggested to be prioritized in preparing clinical guidelines for Iranian colorectal cancer patients. In addition, increasing the basic and supplementary insurance coverage for this drug combination as well as the use of remote technology to guide patients by oncologists can be solutions to reduce direct and indirect costs of the patients.

show abstract

Investigation on the cost–effectiveness of Cetuximab in treatment of colorectal cancer: a systematic review

Alhajj,

Noor,

Md Hanafiah

2024

Colorectal Cancer

View full text Add to dashboard Cite

A Cost Comparison of Biologic Treatment Regimens for Metastatic Colorectal Cancer in Italy

Cited by 3 publications

References 23 publications

Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project

Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran

Investigation on the cost–effectiveness of Cetuximab in treatment of colorectal cancer: a systematic review

Contact Info

Product

Resources

About